Autophagy–Lysosomal Pathway Failure in Brain Disorders: Emerging Mechanisms and Therapeutic Opportunities

Vaishanavi Pangavhane[1], Jubershaha S. Fakir[1], Chandrashekhar D. Patil[1], Kajal V. Pansare[1], Sunil K. Mahajan[1]

Department of Pharmacology, Divine College of Pharmacy, Savitribai Phule Pune University, Maharashtra, India-423301

Abstract- The autophagy lysosomal pathway is a highly conserved intracellular degradation system essential for maintaining neuronal homeostasis and proteostasis. Autophagy delivers cytoplasmic cargo, including misfolded proteins and damaged organelles, to lysosomes for degradation, while lysosomal hydrolases execute terminal breakdown and recycling. Efficient autophagic flux is particularly critical in neurons due to their post-mitotic nature, complex morphology, and high metabolic demand. Disruption of ALP function leads to impaired clearance of toxic proteins, mitochondrial dysfunction, oxidative stress, and neuroinflammation, hallmark features of major neurodegenerative disorders. In Alzheimer's disease, lysosomal acidification defects and impaired autophagosome lysosome fusion contribute to amyloid-β and tau accumulation. In Parkinson's disease, α-synuclein aggregation and mutations in genes such as PINK1, Parkin, and GBA disrupt mitophagy and lysosomal function. Huntington's disease is characterized by mutant huntingtin mediated defects in cargo recognition, vesicular trafficking, and autophagic efficiency. These converging mechanisms result in progressive neuronal degeneration and synaptic dysfunction. Emerging therapeutic strategies aim to restore ALP integrity through enhancement of autophagic flux, correction of lysosomal acidification, activation of transcription factor EB (TFEB), modulation of mTOR and AMPK signaling, and gene therapy–based interventions targeting key autophagy regulators. Collectively, targeting the ALP represents a promising disease-modifying approach for neurodegenerative brain disorders.

Keywords: Autophagy, Huntington's, Alzheimer's, Parkinson's, Neuroinflammation

I.INTRODUCTION

Autophagy and Lysosomal Biology

Autophagy is an evolutionarily conserved catabolic program that delivers cytoplasmic cargo to lysosomes for degradation. Three major autophagic routes exist: macro autophagy, micro autophagy, and chaperone-mediated autophagy, each differing in cargo delivery and regulatory mechanisms. The lysosome, an acidic organelle enriched with hydrolases, executes the final degradative steps and recycles basic metabolites back into the cytosol. Autophagic flux the complete progression from cargo sequestration to lysosomal degradationis essential for cellular homeostasis, especially in long-lived cells such as neurons.

Autophagy and lysosomal biology together constitute the autophagy–lysosomal pathway (ALP), a highly conserved intracellular degradation system essential for maintaining cellular homeostasis. Autophagy is a tightly regulated catabolic process through which cytoplasmic components such as misfolded proteins, damaged organelles, and protein aggregates are sequestered into double-membrane vesicles called autophagosomes, which subsequently fuse with lysosomes for degradation. This process is controlled by key signaling pathways, primarily mTOR and AMPK, which sense nutrient and energy status. The lysosome, an acidic organelle enriched with hydrolytic enzymes such as cathepsins, serves as the terminal degradative compartment where macromolecules are broken down into reusable metabolites. Proper lysosomal acidification via the vacuolar H^+-ATPase is

critical for enzymatic activity. In neurons—long-lived, post-mitotic cells with high metabolic demand-efficient autophagic flux is essential for proteostasis and organelle quality control. Impairment of autophagy or lysosomal function leads to accumulation of toxic protein aggregates and dysfunctional mitochondria, contributing to the pathogenesis of neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Thus, the autophagy–lysosomal system is not only a degradative pathway but also a critical regulator of neuronal survival and brain health [1-3].

II.NEURONAL DEPENDENCE ON AUTOPHAGY–LYSOSOME PATHWAY

Neurons are uniquely sensitive to dysfunction in intracellular clearance systems owing to their complex morphology, polarity, and postmitotic status. Unlike dividing cells that can dilute proteotoxic aggregates by cell division, neurons accumulate damaged proteins and organelles steadily unless robust degradative systems exist. Both autophagy and lysosomal competence decline with age, a primary risk factor for neurodegenerative disorders.

Neurons exhibit a profound dependence on the autophagy–lysosomal pathway (ALP) because they are highly specialized, long-lived, and post-mitotic cells that cannot dilute damaged proteins or organelles through cell division. Unlike proliferating cells, neurons must maintain intracellular quality control for decades, making efficient proteostasis essential for survival. Their complex morphology-including long axons and extensive dendritic arbors-creates additional challenges for intracellular trafficking and degradation. Autophagosomes often form distally in axons and are transported retrogradely along microtubules to the soma, where mature lysosomes are more abundant, highlighting the importance of coordinated vesicular transport and fusion mechanisms. The ALP is critical for clearing misfolded or aggregation-prone proteins, removing dysfunctional mitochondria through mitophagy, and recycling macromolecules to sustain high metabolic demands. Impairment of autophagic flux in neurons leads to accumulation of toxic protein aggregates, oxidative stress, synaptic dysfunction, and activation of neuroinflammatory pathways. Such dysfunction is strongly implicated in neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and Huntington's disease, where defective lysosomal degradation and impaired autophagosome–lysosome fusion contributes to progressive neuronal loss. Therefore, intact autophagy–lysosomal function is indispensable for neuronal longevity, synaptic maintenance, and overall brain homeostasis [4-6].

III.MOLECULAR MECHANISMS OF ALP DYSFUNCTION IN BRAIN DISORDERS

Dysfunction of the autophagy–lysosomal pathway (ALP) in brain disorders occurs at multiple molecular levels, including impaired autophagy initiation, defective cargo recognition, disrupted vesicle trafficking, failed autophagosome–lysosome fusion, lysosomal acidification defects, and enzymatic insufficiency. Because neurons are post-mitotic and metabolically active, even subtle defects in any of these steps can result in progressive accumulation of toxic proteins and damaged organelles.

One major mechanism involves defective autophagy initiation signaling. The mTOR pathway negatively regulates autophagy, while AMPK promotes it during energy stress. In neurodegenerative diseases, chronic mTOR hyperactivation or impaired AMPK signaling reduces autophagosome formation, limiting the cell’s ability to clear misfolded proteins. Reduced expression or dysfunction of core autophagy proteins such as ULK1, Beclin-1, and ATG complexes has been reported in conditions like Alzheimer's disease.

A second critical defect occurs in cargo recognition and selective autophagy. Adaptor proteins such as p62/SQSTM1 link ubiquitinated proteins to LC3 on the autophagosome membrane. Mutations or overload of aggregation-prone proteins can overwhelm this system, leading to accumulation of inclusions. For example, α-synuclein aggregates in Parkinson's disease impair both macro autophagy and chaperone-mediated autophagy by blocking lysosomal receptors such as LAMP-2A.

Another major mechanism is impaired autophagosome–lysosome fusion. Fusion requires Rab7, SNARE proteins, and the HOPS complex. Disruption of these molecular mediators'results in accumulation of autophagic vacuoles, a hallmark observed in several neurodegenerative disorders. In Huntington's disease, mutant huntingtin interferes with vesicle trafficking and autophagic cargo loading, reducing autophagic efficiency despite autophagosome formation.

Lysosomal dysfunction represents a central downstream mechanism. Proper lysosomal degradation depends on acidic luminal pH maintained by the vacuolar H^+-ATPase (v-ATPase). In some familial forms of Alzheimer's disease, mutations in presenilin-1 disrupt lysosomal acidification, leading to reduced activity of hydrolases such as cathepsins. Impaired acidification prevents efficient degradation, causing build-up of amyloid-β and tau.

Additionally, defective lysosomal biogenesis and transcriptional regulation contribute to ALP failure. The transcription factor TFEB regulates genes involved in lysosomal formation and autophagy. Reduced nuclear translocation of TFEB diminishes lysosomal capacity and clearance efficiency, promoting proteotoxic stress.

Another important mechanism involves mitophagy impairment. Proteins such as PINK1 and Parkin regulate selective removal of damaged mitochondria. Mutations in these genes, particularly in Parkinson's disease, compromise mitochondrial quality control, resulting in oxidative stress and neuronal vulnerability [7-9].

IV.GENERAL ALP FAILURE MECHANISMS

ALP failure in brain disorders may occur at multiple points:

- Impaired initiation of autophagy (e.g., defective signaling or phagophore formation)
- Blocked autophagosome–lysosome fusion
- Defective lysosomal acidification and hydrolase function
- Genetic mutations that disrupt vesicular trafficking
- Accumulation of toxic aggregates that physically impede lysosomal function

General failure of the autophagy–lysosomal pathway (ALP) in brain disorders occurs through multiple interconnected molecular defects that impair intracellular degradation and recycling. One primary mechanism is impaired autophagy initiation, often resulting from dysregulation of mTOR and AMPK signaling pathways, which control ULK1 activation and autophagosome formation. Reduced expression or dysfunction of core autophagy-related (ATG) proteins and Beclin-1 further limits phagophore nucleation. A second common defect involves abnormal cargo recognition and selective autophagy, where adaptor proteins such as p62/SQSTM1 fail to efficiently link ubiquitinated substrates to LC3, leading to accumulation of protein aggregates. Another major mechanism is defective autophagosome–lysosome fusion, frequently caused by disruption of Rab7, SNARE proteins, or cytoskeletal transport systems, resulting in accumulation of immature autophagic vacuoles. Additionally, lysosomal dysfunction plays a central role; impaired acidification due to vacuolar H^+-ATPase malfunction reduces hydrolase activity, compromising degradation efficiency. Altered lysosomal membrane integrity, defective cathepsin processing, and impaired lysosomal biogenesis—often linked to reduced TFEB activation—further weaken degradative capacity. Age-related decline in lysosomal enzyme activity and membrane stability exacerbates these defects. Collectively, these mechanisms converge to cause reduced autophagic flux, accumulation of toxic proteins, mitochondrial dysfunction, oxidative stress, and progressive neuronal degeneration in various brain disorders.

These defects converge on an inability to clear proteinaceous waste, leading to cellular stress, organelle dysfunction, oxidative damage, and, ultimately, neuronal death [10-12].

V.ALZHEIMER'S DISEASE

AD is characterized by extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. Autophagy and lysosomal failure are central to AD pathogenesis:

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. It is clinically characterized by progressive memory loss, cognitive decline, impaired reasoning, and behavioral disturbances. Pathologically, AD is defined by two hallmark lesions: extracellular amyloid-β (Aβ) plaques and intracellular neurofibrillary tangles composed of hyperphosphorylated tau protein. These pathological features are accompanied by synaptic loss, neuroinflammation, mitochondrial dysfunction, and widespread neuronal degeneration, particularly in the hippocampus and cerebral cortex.

At the molecular level, AD is strongly associated with dysfunction of the autophagy–lysosomal pathway (ALP). Impaired autophagic flux leads to accumulation of autophagic vacuoles within neurons, especially in dystrophic neurites. One major defect involves lysosomal acidification failure, often linked to presenilin-1 (PSEN1) mutations in familial AD. Defective vacuolar H^+-ATPase activity increases lysosomal pH, reducing the activity of hydrolytic enzymes such as cathepsins, thereby impairing degradation of Aβ and tau. As a result, autophagosomes accumulate without effective clearance.

Additionally, abnormal processing of amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase leads to excessive production of Aβ peptides, particularly Aβ42, which aggregate and form plaques. These aggregates further disrupt lysosomal membrane integrity and autophagosome–lysosome fusion, creating a vicious cycle of proteotoxic stress. Hyperphosphorylated tau destabilizes microtubules, impairing axonal transport of autophagosomes to lysosome-rich regions in the soma, thereby worsening clearance deficits.

Neuroinflammation also plays a critical role in AD progression. Activated microglia respond to Aβ deposition, releasing pro-inflammatory cytokines that exacerbate neuronal injury and further impair autophagic and lysosomal function. Mitochondrial dysfunction and oxidative stress contribute additional layers of cellular damage.

Lysosomal Acidification Defects: Mutations in *PSEN1* disrupt the vacuolar H^+-ATPase (v-ATPase) complex responsible for lysosomal acidification. Elevated lysosomal pH impairs degradative enzyme activity, leading to reduced clearance of Aβ and other cargo.

Autophagosome Accumulation: Impaired autophagosome–lysosome fusion results in build-up of autophagic vacuoles. These stalled compartments accumulate neurotoxic substrates within neurons.

Vicious Cycle of Protein Accumulation: Aβ and tau aggregates further inhibit autophagy and lysosomal fusion mechanisms, establishing a pathological feedback loop that accelerates neuronal toxicity.

Cathepsin Dysregulation: Lysosomal hydrolases such as Cathepsins D and B become mis localized or inactivated, further impeding protein degradation.

Collectively, AD represents a model in which ALP failure precedes and amplifies hallmark neuropathology [13-14].

VI.PARKINSON'S DISEASE

Parkinson's disease (PD) is a progressive neurodegenerative disorder primarily characterized by motor symptoms including bradykinesia, resting tremor, rigidity, and postural instability, along with non-motor symptoms such as cognitive impairment and autonomic dysfunction. The pathological hallmark of PD is the selective degeneration of dopaminergic neurons in the substantia nigra pars compacta and the presence of intracellular inclusions known as Lewy bodies, which are mainly composed of aggregated α-synuclein. Increasing evidence indicates that dysfunction of the autophagy–lysosomal

pathway (ALP) plays a central role in PD pathogenesis.

Under physiological conditions, α-synuclein is degraded through both macro autophagy and chaperone-mediated autophagy (CMA). However, mutant or aggregated α-synuclein impairs its own degradation by binding to lysosomal receptors such as LAMP-2A, thereby blocking CMA and reducing lysosomal efficiency. Accumulation of α-synuclein further disrupts autophagosome formation and fusion, leading to impaired autophagic flux. Genetic mutations linked to familial PD-including PINK1, Parkin, LRRK2, and GBA-directly affect ALP components. PINK1 and Parkin regulate mitophagy, the selective removal of damaged mitochondria; their dysfunction results in mitochondrial accumulation, oxidative stress, and neuronal vulnerability. Mutations in GBA (encoding glucocerebrosidase) reduce lysosomal enzyme activity, impair substrate degradation, and promote α-synuclein aggregation, creating a pathogenic feedback loop. Additionally, impaired lysosomal acidification and defective vesicular trafficking contribute to accumulation of autophagic vacuoles in affected neurons.

In PD, loss of dopaminergic neurons and accumulation of α-synuclein-rich Lewy bodies are classic features. Dysfunction of the ALP plays a significant causal role:

- α-Synuclein Clearance: Wild-type and mutant forms of α-synuclein are substrates for both the proteasome and ALP. Pathogenic mutations or increased protein levels saturate ALP capacity, promoting aggregation.
- Genetic Influences: Mutations in ALP-associated genes (*LRRK2*, *PINK1*, *Parkin*) further exacerbate autophagic failure and mitochondrial quality control deficits, contributing to dopaminergic neuron loss.
- Impaired Autophagosome–Lysosome Fusion: Defective fusion events have been observed in PD models, leading to autophagic vesicle accumulation reminiscent of those seen in AD.

VII.HUNTINGTON'S DISEASE

Huntington's disease (HD) is an autosomal dominant, progressive neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene, which encodes the huntingtin protein. The mutation results in an elongated polyglutamine (polyQ) tract in mutant huntingtin (mHTT), leading to protein misfolding, aggregation, and neuronal toxicity. Clinically, HD is characterized by choreiform movements, cognitive decline, psychiatric disturbances, and progressive functional deterioration. Neuropathologically, there is selective degeneration of medium spiny neurons in the striatum and later involvement of cortical regions.

A central pathogenic mechanism in HD is dysfunction of the autophagy–lysosomal pathway (ALP). Although autophagosomes may form in HD neurons, their cargo recognition and loading are often defective. Mutant huntingtin interferes with the recruitment of adaptor proteins such as p62 and disrupts selective autophagy, resulting in inefficient sequestration of damaged proteins and organelles. Additionally, mHTT impairs vesicular trafficking along microtubules, affecting autophagosome transport and autophagosome–lysosome fusion. Lysosomal positioning and function are also altered, leading to reduced degradative capacity. Evidence suggests that mHTT can dysregulate mTOR signaling, further disturbing autophagy initiation and flux. Impaired mitophagy contributes to accumulation of dysfunctional mitochondria, increasing oxidative stress and energy deficits in vulnerable neurons.

Thus, Huntington's disease exemplifies a condition in which defective cargo recognition, impaired vesicle dynamics, altered signaling pathways, and lysosomal dysfunction converge to reduce autophagic efficiency. Restoration of proper autophagic flux and enhancement of lysosomal function are therefore considered promising therapeutic strategies for slowing HD progression.

HD results from expanded polyglutamine repeats in huntingtin protein (mHTT), which misfolds and forms deposits:

- Lysosomal System Disruption: mHTT alters lysosomal positioning and trafficking, disrupting mTORC1 regulation and lysosomal activity.
- Reduced Autophagic Flux: Transcriptomic analyses show downregulation of ALP genes and functional evidence of reduced autophagy in HD models.

The combined effect of aggregation-prone proteins and disrupted ALP exacerbates neuronal dysfunction and degeneration in HD [15-16].

VIII.PATHOLOGICAL CONSEQUENCES OF ALP FAILURE

Failure of the autophagy–lysosomal pathway (ALP) leads to profound pathological consequences, particularly in neurons, which rely heavily on efficient intracellular clearance mechanisms. One of the primary outcomes is accumulation of misfolded and aggregation-prone proteins, such as amyloid-β and tau in Alzheimer's disease, α-synuclein in Parkinson's disease, and mutant huntingtin in Huntington's disease. When autophagic flux is impaired—due to defective autophagosome formation, fusion failure, or lysosomal dysfunction—these toxic proteins accumulate and form intracellular inclusions, disrupting cellular architecture and signaling pathways.

Another major consequence is mitochondrial dysfunction. Impaired mitophagy prevents removal of damaged mitochondria, leading to excessive production of reactive oxygen species (ROS), oxidative stress, and energy deficits. Neurons, which have high metabolic demands, are particularly vulnerable to such mitochondrial impairment. Persistent oxidative stress damages lipids, proteins, and DNA, further accelerating neuronal injury.

ALP failure also contributes to synaptic dysfunction and axonal transport defects. Accumulation of autophagic vacuoles and aggregated proteins interferes with microtubule stability and vesicular trafficking, impairing neurotransmitter release and synaptic plasticity. This synaptic loss strongly correlates with cognitive decline in neurodegenerative diseases.

Additionally, dysfunctional lysosomes may undergo membrane permeabilization, releasing cathepsins into the cytoplasm and triggering apoptotic or necrotic pathways. Chronic activation of these stress pathways ultimately leads to neuronal apoptosis and neurodegeneration.

Another important pathological outcome is neuroinflammation. Accumulated protein aggregates activate microglia and astrocytes, promoting release of pro-inflammatory cytokines that exacerbate neuronal damage. This creates a vicious cycle in which inflammation further impairs autophagy and lysosomal function [17-18].

IX.PROTEIN AGGREGATION AND TOXICITY

Protein aggregation and toxicity represent central pathological consequences of autophagy–lysosomal pathway (ALP) dysfunction in brain disorders. Under normal physiological conditions, molecular chaperones, the ubiquitin–proteasome system, and autophagy work together to maintain proteostasis by ensuring proper protein folding and timely degradation of misfolded or damaged proteins. When autophagic flux is impaired—due to defective autophagosome formation, disrupted fusion with lysosomes, or lysosomal acidification failure—misfolded and aggregation-prone proteins accumulate in the cytoplasm. These proteins undergo conformational changes that promote oligomerization and formation of insoluble aggregates or inclusions.

Toxic protein aggregates interfere with multiple cellular processes. Soluble oligomeric intermediates are particularly harmful, as they disrupt membrane integrity, alter calcium homeostasis, impair synaptic signaling, and trigger oxidative stress. Aggregates can sequester essential cellular proteins, including chaperones and transcription factors, thereby disrupting normal cellular function. In addition, protein inclusions obstruct intracellular trafficking pathways, including axonal transport, which is critical for neuronal survival.

In neurodegenerative diseases, specific aggregation-prone proteins accumulate: amyloid-β and hyperphosphorylated tau in Alzheimer's disease, α-

synuclein in Parkinson's disease, and mutant huntingtin in Huntington's disease. These aggregated proteins not only result from ALP impairment but also further inhibit autophagy and lysosomal function, creating a vicious cycle of proteotoxic stress. Persistent aggregation ultimately activates apoptotic signaling pathways, mitochondrial dysfunction, neuroinflammation, and progressive neuronal degeneration.

Failure to clear aggregation-prone proteins (e.g., Aβ, tau, α-synuclein, mHTT) accelerates their accumulation, forming toxic inclusions that disrupt synaptic functions, trigger oxidative stress, and activate inflammatory responses [19-20].

X.MITOCHONDRIAL DYSFUNCTION AND ENERGETIC STRESS

Mitochondrial dysfunction and energetic stress are major pathological consequences of impaired autophagy–lysosomal pathway (ALP) activity in neurodegenerative disorders. Mitochondria are essential for ATP production through oxidative phosphorylation, regulation of calcium homeostasis, generation of metabolic intermediates, and control of apoptotic signaling. In healthy neurons, damaged or depolarized mitochondria are selectively removed through mitophagy, a specialized form of autophagy primarily regulated by PINK1 and Parkin. When ALP function is compromised, defective mitochondria accumulate within neurons, leading to excessive production of reactive oxygen species (ROS), oxidative damage to lipids and proteins, and impaired ATP synthesis.

Neurons are particularly vulnerable to energetic failure because of their high metabolic demand and dependence on mitochondrial ATP for synaptic transmission, axonal transport, and maintenance of ion gradients. Accumulation of dysfunctional mitochondria disrupts calcium buffering capacity, causing excitotoxicity and activation of cell death pathways. In Parkinson's disease, mutations in PINK1 and Parkin impair mitophagy, promoting mitochondrial fragmentation and oxidative stress in dopaminergic neurons. Similarly, in Alzheimer's disease and Huntington's disease, mitochondrial abnormalities-including reduced respiratory chain activity and increased oxidative injury-are strongly linked to defective autophagic clearance.

Energetic stress further activates AMPK and other stress pathways; however, chronic impairment of autophagic flux prevents adequate mitochondrial turnover, leading to a vicious cycle of ROS accumulation, inflammation, and neuronal degeneration. Ultimately, sustained mitochondrial dysfunction compromises cellular bioenergetics, promotes apoptotic signaling, and accelerates progressive neurodegeneration. Restoration of mitophagy and lysosomal function is therefore considered a promising therapeutic strategy to alleviate energetic deficits and oxidative stress in brain disorders.

Defective autophagy leads to impaired mitophagy, allowing dysfunctional mitochondria to persist and release reactive oxygen species (ROS), which further damage cellular components [21-22].

XI.NEUROINFLAMMATION

Neuroinflammation is a prominent pathological consequence of autophagy–lysosomal pathway (ALP) dysfunction in neurodegenerative brain disorders. Under physiological conditions, autophagy regulates immune homeostasis by removing damaged mitochondria, inflammasome components, and aggregated proteins that could otherwise trigger inflammatory responses. When ALP function is impaired, accumulation of protein aggregates and dysfunctional organelles acts as danger-associated molecular patterns (DAMPs), activating microglia and astrocytes. These activated glial cells release pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6, as well as reactive oxygen and nitrogen species, thereby amplifying neuronal injury.

Defective mitophagy contributes significantly to neuroinflammation. Damaged mitochondria release mitochondrial DNA and ROS, which activate inflammasome complexes such as NLRP3, further promoting cytokine maturation and secretion. In Alzheimer's disease, amyloid-β aggregates stimulate chronic microglial activation, while impaired

lysosomal degradation exacerbates inflammatory signaling. Similarly, in Parkinson's disease, α-synuclein accumulation and mitochondrial dysfunction activate innate immune pathways, contributing to dopaminergic neuron loss. Persistent neuroinflammation not only accelerates neuronal degeneration but also further disrupts autophagic and lysosomal processes, creating a self-perpetuating cycle of inflammation and proteotoxic stress. Stalled degradation and neuronal death stimulate glial activation and chronic inflammation, contributing to neurodegeneration progression.

XII.THERAPEUTIC STRATEGIES TARGETING THE ALP

Targeting the autophagy–lysosomal pathway (ALP) has emerged as a promising therapeutic strategy for neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, where defective clearance of misfolded proteins and damaged organelles plays a central pathogenic role. Therapeutic approaches aim either to enhance autophagic flux, restore lysosomal function, or correct upstream regulatory defects.

One major strategy involves pharmacological induction of autophagy, particularly through inhibition of the mechanistic target of rapamycin (mTOR) pathway. mTOR negatively regulates autophagy; thus, its inhibition promotes autophagosome formation. Agents such as Rapamycin and its analogs (rapalogs) stimulate autophagy and have shown neuroprotective effects in preclinical models by enhancing clearance of amyloid-β, α-synuclein, and mutant huntingtin aggregates. Similarly, AMPK activators like Metformin indirectly induce autophagy by suppressing mTOR signaling and improving cellular energy homeostasis.

Another therapeutic approach focuses on enhancing lysosomal biogenesis and function. The transcription factor EB (TFEB) is a master regulator of lysosomal gene expression and autophagy-related genes. Pharmacological or genetic activation of TFEB enhances lysosomal acidification, increases degradative capacity, and improves clearance of toxic protein aggregates. Small molecules that promote TFEB nuclear translocation are being explored as potential disease-modifying therapies.

Targeting selective autophagy pathways, such as mitophagy, also holds promise. Impaired mitophagy contributes to mitochondrial dysfunction and oxidative stress in Parkinsonian disorders. Agents that enhance PINK1–Parkin signaling or stabilize mitochondrial quality control mechanisms may restore neuronal energy balance and reduce neurodegeneration.

Gene therapy represents an advanced strategy to correct ALP dysfunction at its source. For example, viral vector–mediated delivery of lysosomal enzymes or autophagy-regulating genes is under investigation, particularly for lysosomal storage disorders and certain inherited neurodegenerative diseases. Enhancing glucocerebrosidase activity has been explored in Parkinson's disease models associated with GBA mutations [23-26].

XIII.ENHANCING AUTOPHAGIC FLUX

Enhancing autophagic flux refers to stimulating the complete process of autophagy—from autophagosome formation to lysosomal degradation—so that damaged proteins and organelles are efficiently cleared from neurons. In many neurodegenerative disorders, autophagosomes accumulate not because autophagy is overactive, but because the degradative step is impaired. Therefore, therapeutic strategies aim to restore functional flux rather than simply increase autophagosome numbers.

One major approach involves inhibition of the mechanistic target of rapamycin (mTOR), a central negative regulator of autophagy. Under nutrient-rich conditions, mTOR suppresses autophagy initiation. Pharmacological inhibitors such as Rapamycin activate ULK1 and downstream autophagy machinery, promoting autophagosome formation and enhancing clearance of toxic aggregates in models of Alzheimer's disease, Parkinson's disease, and Huntington's disease. Similarly, activation of AMP-activated protein kinase (AMPK) using agents like Metformin induces autophagy indirectly by

suppressing mTOR and improving cellular energy sensing.

Another strategy focuses on mTOR-independent pathways. Compounds such as trehalose enhance autophagy through transcriptional activation of autophagy-related genes without directly inhibiting mTOR, potentially reducing side effects associated with chronic mTOR suppression. Additionally, activation of transcription factor EB (TFEB), a master regulator of lysosomal biogenesis and autophagy genes, improves autophagosome–lysosome fusion and enhances degradative capacity. Promoting TFEB nuclear translocation has shown promise in preclinical neurodegenerative models.

Importantly, enhancing autophagic flux must ensure effective lysosomal function, including proper acidification and enzyme activity. Therapies that restore lysosomal pH, increase hydrolase activity, or improve autophagosome–lysosome fusion help prevent the pathologicalaccumulation of undegraded cargo. Because neurons are long-lived and highly dependent on proteostasis, restoring efficient autophagic flux is considered a key disease-modifying approach for neurodegenerative brain disorders [27-28].

Approaches include:

- mTORC1 inhibition (e.g., rapamycin and analogues) to induce autophagy
- TFEB activation to upregulate lysosomal biogenesis Both strategies aim to bolster degradative capacity and have shown promise in experimental models.

XIV.LYSOSOMAL ACIDIFICATION AND HYDROLASE FUNCTION

Lysosomal acidification is a fundamental requirement for proper autophagy–lysosomal pathway (ALP) function. Lysosomes maintain an acidic luminal pH (~4.5–5.0), which is essential for activating lysosomal hydrolases—proteases, lipases, nucleases, and glycosidases responsible for degrading autophagic cargo. This acidic environment is primarily maintained by the vacuolar-type H^+-ATPase (V-ATPase), a proton pump that actively transports hydrogen ions into the lysosomal lumen. Any disruption in V-ATPase function, membrane integrity, or ion homeostasis can elevate lysosomal pH, impair enzyme activation, and reduce degradative efficiency.

Lysosomal hydrolases such as cathepsins (e.g., cathepsin D, B, and L) require acidic conditions for optimal catalytic activity. In neurodegenerative disorders, defective acidification leads to reduced hydrolase activity, resulting in incomplete degradation of proteins such as amyloid-β, α-synuclein, and mutant huntingtin. This contributes to the accumulation of toxic aggregates observed in Alzheimer's disease, Parkinson's disease, and Huntington's disease. Impaired lysosomal pH regulation also affects autophagosome–lysosome fusion and cargo processing, further disrupting autophagic flux.

Genetic mutations affecting lysosomal enzymes or trafficking proteins can directly compromise hydrolase delivery and maturation. For example, mutations in genes encoding lysosomal proteins may impair enzyme processing in the endoplasmic reticulum and Golgi apparatus, leading to reduced enzymatic activity within lysosomes. Additionally, oxidative stress and lipid peroxidation can damage lysosomal membranes, causing proton leakage and further alkalinization.

Therapeutically, restoring lysosomal acidification and hydrolase activity is considered a promising strategy. Approaches include enhancing V-ATPase function, activating transcription factor EB (TFEB) to promote lysosomal biogenesis, and increasing the expression or stability of lysosomal enzymes. Improving lysosomal pH homeostasis not only restores proteolytic degradation but also reduces protein aggregation, mitochondrial dysfunction, and neuroinflammation associated with ALP failure.

Restoration of lysosomal pH homeostasis and cathepsin activity is under investigation to improve cargo degradation, particularly in AD models [29-30].

XV.SMALL MOLECULES AND GENE THERAPIES

Emerging small-molecule ALP modulators and gene therapy techniques targeting ALP components (e.g., TFEB gene delivery) are in preclinical or early clinical evaluation.

Small molecules and gene-based therapies represent two rapidly advancing strategies aimed at restoring autophagy–lysosomal pathway (ALP) function in neurodegenerative disorders. Because ALP dysfunction contributes to toxic protein accumulation, mitochondrial damage, and neuroinflammation, pharmacological and genetic interventions seek to enhance autophagic flux, improve lysosomal activity, or correct underlying genetic defects.

Small Molecules Targeting ALP

Small-molecule modulators primarily act by stimulating autophagy initiation, enhancing lysosomal biogenesis, or improving degradative efficiency. mTOR inhibitors such as Rapamycin induce autophagy by relieving mTOR-mediated suppression of ULK1, thereby promoting autophagosome formation. AMPK activators like Metformin stimulate autophagy indirectly through metabolic stress signaling and mTOR inhibition.

Other compounds act independently of mTOR. Trehalose enhances autophagy through transcriptional activation of autophagy-related genes and has shown benefit in experimental models of Huntington's disease. Small molecules that activate transcription factor EB (TFEB) promote lysosomal biogenesis and acidification, thereby restoring autophagosome–lysosome fusion and degradative capacity. In Parkinson's disease, pharmacological enhancement of glucocerebrosidase (GCase) activity has been explored to improve lysosomal enzyme function and reduce α-synuclein accumulation.

Additionally, compounds targeting selective autophagy—such as mitophagy enhancers—are being developed to restore mitochondrial quality control, particularly relevant in Parkinsonian disorders associated with PINK1–Parkin pathway defects.

Gene Therapies Targeting ALP

Gene therapy approaches aim to correct ALP dysfunction at the molecular level. Viral vectors, particularly adeno-associated viruses (AAVs), are used to deliver genes encoding lysosomal enzymes, autophagy regulators, or transcription factors such as TFEB. Overexpression of TFEB has demonstrated improved lysosomal clearance and reduced protein aggregation in preclinical models of Alzheimer's disease and Huntington's disease[31-32].

In Parkinson's disease associated with GBA mutations, gene therapy strategies aim to restore glucocerebrosidase expression to normalize lysosomal function. Similarly, RNA-based therapies, including antisense oligonucleotides (ASOs), are being investigated to reduce mutant protein production while supporting proteostatic mechanisms [33-36].

XVI.CONCLUSIONS

The autophagy–lysosomal pathway (ALP) is a fundamental intracellular degradation system that safeguards neuronal integrity by maintaining proteostasis, organelle quality control, and metabolic balance. Because neurons are long-lived and post-mitotic, they rely heavily on efficient autophagic flux and proper lysosomal function to prevent accumulation of damaged proteins and organelles. Disruption at any stage of the ALP-including impaired autophagy initiation, defective cargo recognition, failed autophagosome–lysosome fusion, lysosomal acidification defects, or reduced hydrolase activity-can lead to progressive cellular stress and neuronal vulnerability.

Compelling evidence indicates that ALP dysfunction plays a central pathogenic role in major neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. In these conditions, accumulation of aggregation-prone proteins, mitochondrial dysfunction, oxidative stress, and neuroinflammation are closely linked to defective intracellular clearance mechanisms. Importantly, ALP failure is not merely a secondary consequence of disease but often contributes directly to disease initiation and progression through self-amplifying cycles of proteotoxic and inflammatory stress.

Therapeutic strategies targeting the ALP-including mTOR modulation, TFEB activation, restoration of lysosomal acidification, enhancement of mitophagy, and gene therapy approaches-offer promising avenues for disease modification. Rather than addressing only downstream symptoms, these strategies aim to correct the underlying defects in cellular quality control systems.

In conclusion, preservation and restoration of autophagy-lysosomal function represent a critical frontier in neurodegenerative research. A deeper mechanistic understanding of ALP regulation and dysfunction will be essential for developing effective, targeted therapies capable of slowing or halting progressive neuronal loss in brain disorders.

REFERENCES

[1] Mizushima N, Levine B. Autophagy in human diseases. N Engl J Med. 2020;383(16):1564–1576.

[2] Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997.

[3] Settembre C, Fraldi A, Medina DL, Ballabio A. Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 2013;14(5):283–296.

[4] Nixon RA. The role of autophagy in neurodegenerative disease. *Nat Med*. 2013;19(8):983-997.

[5] Wolfe DM, Lee JH, Kumar A, et al. Autophagy failure in Alzheimer's disease and the role of defective lysosomal acidification. *Eur J Neurosci*. 2013;37(12):1949-1961.

[6] Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. *Brain*. 2008;131(8):1969-1978.

[7] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. *Int J Mol Sci*. 2026;27(1):366.

[8] Jung YK, Kim SH, Cho YS. Failure of lysosomal acidification and endomembrane network in neurodegeneration. *Exp Mol Med*. 2025; 57:2418–2428.

[9] Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. *Nat Rev Mol Cell Biol*. 2024;25(11):926–946.

[10] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. *Int J Mol Sci*. 2026;27(1):366.

[11] Mançano ASF, Pina JG, Froes BR, Sciani JM. Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer's disease. *Front Mol Biosci*. 2024;11:1490275.

[12] Kim Y, Ha TY, Lee MS, Chang KA. Regulatory mechanisms and therapeutic implications of lysosomal dysfunction in Alzheimer's disease. *Int J Biol Sci*. 2025;21(3):1014-1031.

[13] Jiao F, Meng L, Du K, Li X. The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson's disease. *Neural Regen Res*. 2025;20(1):139–158.

[14] Zhang X, Le W. Advances in understanding the molecular mechanisms of autophagy in Parkinson's disease. *Ageing and Neurodegenerative Diseases*. 2025.

[15] Berg MJ, Veeranna, Rosa CM, Kumar A, Mohan PS, Stavrides P, et al. Pathobiology of the autophagy-lysosomal pathway in the Huntington's disease brain. Acta NeuropatholCommun. 2025;13:228.

[16] Alshehabi Y, Martin DD, et al. Protective proteolysis in Huntington's disease: unraveling the role of post-translational myristoylation of huntingtin in autophagy. J Huntingtons Dis. 2024;13(3):267-277.

[17] Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. *Nat Rev Mol Cell Biol*. 2024;25(11):926–946.

[18] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. *Int J Mol Sci*. 2026;27(1):366.

[19] Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25(11):926–946.

[20] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and

cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2026;27(1):366.

[21] Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25(11):926–946.

[22] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2026;27(1):366.

[23] Nixon RA, Rubinsztein DC. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases. Nat Rev Mol Cell Biol. 2024;25(11):926–946.

[24] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2026;27(1):366.

[25] Du M, Yu Y, Wang J, Ji C. Autophagy–Lysosome Pathway Dysfunction in Neurodegeneration and Cancer: Mechanisms and Therapeutic Opportunities. Int J Mol Sci. 2026;27(1):366.

[26] Jiao F, Meng L, Du K, Li X. The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson's disease. Neural Regen Res. 2025;20(1):139–158.

[27] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2026;27(1):366.

[28] Jiao F, Meng L, Du K, Li X. The autophagy–lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson's disease. Neural Regen Res. 2025;20(1):139–158.

[29] Mançano ASF, Pina JG, Froes BR, Sciani JM. Autophagy-lysosomal pathway impairment and cathepsin dysregulation in Alzheimer's disease. Front Mol Biosci. 2024;11:1490275.

[30] Du M, Yu Y, Wang J, Ji C. Autophagy–lysosome pathway dysfunction in neurodegeneration and cancer: mechanisms and therapeutic opportunities. Int J Mol Sci. 2026;27(1):366.

[31] Fengjuan Jiao, Lingyan Meng, Kang Du, Xuezhi Li. The autophagy-lysosome pathway: a potential target in the chemical and gene therapeutic strategies for Parkinson's disease. Neural Regen Res. 2025;20(1):139–158.

[32] Shumayila Khan, Saurabh Upadhyay, Md Imtaiyaz Hassan. Novel prospects in targeting neurodegenerative disorders via autophagy. Eur J Pharmacol. 2024;984:177060.

[33] Khairnar SS, Saad M, Fakir JS, Ahire YS, Ataurrahman Z, Patil NK. Hepatoprotective properties of polyherbal extract: a promising approach for liver necrosis management. *Int J Pharm Investig.* 2024;14(3):759–767.

[34] Fakir JS, Chavan D, Kalam A, Davange M, Kundgir V, Khairnar H. Gastric adenocarcinoma: the use of animal models to research risk factors, prevention, and treatment approaches. *Int J Med Pharm Sci.* 2026;2(3):22–32.

[35] Pawar M, Patil C, Fakir Z, Pagar D, Mahajan S. GLP-1 receptor agonists: advances in mechanism, therapeutic applications, and future perspectives. *BioMed Target J.* 2025;3(2):18–22.

[36] Fakir JS, Ahire CM, Surana KR, Kalam A, Ahamad AA, Davange MD, Mahajan SK. Formulation and evaluation of antibacterial and anti-inflammatory emulgel containing *Eugenia caryophyllus* buds extract. *Biotech Res Asia.* 2024; 21(3).